{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:25:37Z","timestamp":1773681937471,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T00:00:00Z","timestamp":1133827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Few new drugs for treatment of Langerhans cell histiocytosis (LCH) have been studied. Tumor necrosis factor\u2010alpha (TNF\u2010\u03b1) is a prime therapeutic target since it appears to be present in elevated amounts in LCH lesions. Thalidomide inhibits TNF\u2010\u03b1 production by affecting the gene promoter as well as other anti\u2010cytokine effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedures<\/jats:title><jats:p>A Phase II trial of thalidomide for treatment of LCH patients who had failed primary and at least one secondary regimen was conducted. Sixteen patients were enrolled: nine males and seven females ranging in age from 19 months to 45 years. Six patients were high risk (HR) because of spleen, liver, lung, or bone marrow involvement. The low risk (LR) patients included six with bone\/skin LCH, one with multiple bone, one with skin\/bone\/pituitary, one with skin\/bone\/brain, and one with skin only disease involvement. Fifteen patients remained on treatment from 3 weeks to over 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the LR patients there were four complete responses, three partial responses, and two with no response to thalidomide. No HR patient responded to thalidomide and all died of pulmonary, liver, or bone marrow failure. Thalidomide may have played a role in the pulmonary failure. Other toxicities that required stopping therapy included neutropenia, peripheral neuropathy, and fatigue.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Thalidomide is an effective therapy for some LR patients with LCH, but showed no significant responses in HR patients. Dose\u2010limiting toxicities may reduce its efficacy in LR patients. Additional trials with improved anti\u2010TNF therapies would appear warranted. Pediatr Blood Cancer 2007;48:44\u201349. \u00a9 2005 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20578","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T20:58:46Z","timestamp":1133902726000},"page":"44-49","source":"Crossref","is-referenced-by-count":69,"title":["A phase II trial using thalidomide for Langerhans cell histiocytosis"],"prefix":"10.1002","volume":"48","author":[{"given":"Kenneth L.","family":"McClain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia A.","family":"Kozinetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-84520-8_22"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230203"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1178"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1241"},{"key":"e_1_2_6_6_2","first-page":"4195","article-title":"Differential in situ cytokine profiles of Langerhans\u2010like cells and T cells in Langerhans cell histiocytosis: Abundant expression of cytokines relevant to disease and treatment","volume":"94","author":"Egeler RM","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/360258a0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.0181"},{"key":"e_1_2_6_9_2","first-page":"1387","article-title":"Histiocytose X avec \u2018granulome \u00e9osinophile vulvair\u00e9\u2019. Effet spectaculaire de la thalidomide","volume":"114","author":"Gnassia A","year":"1987","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_6_10_2","first-page":"281","article-title":"Langerhans\u2010cell histiocytosis in the adult: Regressive parotid involvement following thalidomide therapy","volume":"119","author":"Bensaid P","year":"1992","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1993.tb02262.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archderm.1993.01680310031004","article-title":"Successful treatment of adult's Langerhans cell histiocytosis with thalidomide","volume":"129","author":"Thomas L","year":"1993","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb08659.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001050050696"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001050050298"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00370-6"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.pgp.0000130042.31203.b0"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076491"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5070\/D34Z68Q2BQ","article-title":"Langerhans cell histiocytosis","volume":"8","author":"Mortazavi H","year":"2002","journal-title":"Dermatol Online J"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/000155502320624186"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(02)00627-6"},{"key":"e_1_2_6_22_2","first-page":"1008","article-title":"Thalidomide and thrombosis: Three observations","volume":"30","author":"Pouaha J","year":"2001","journal-title":"Presse Med"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200105000-00004"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(97)80720-5"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00358.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006293422607"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.3.699"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb05527.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90122-X"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204163261604"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701138"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20578","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T13:17:42Z","timestamp":1700054262000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1002\/pbc.20578"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20578","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,6]]}}}